A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

Association between targeted cancer drug net health benefit and uptake, patient out-of-pocket spending, and total spending. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. A prognostic factor (PF) index for overall survival in a HER2-negative ...

The journey from AML diagnosis to recovery emphasized self-advocacy, emotional resilience, and a positive mindset as crucial elements for survival and healing. Setting personal boundaries and ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...